source
- Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug dosesThe two biggest players in the obesity market are headed to court. Novo Nordisk sued Eli Lilly on Tuesday over what it claims are “maliciously and deceptively false” ads comparing the highest doses…Endpoints · 11d ago↗ source
- STAT+: Rare disease drugmakers try to avoid Trump price cutsPlus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.STAT · 11d ago↗ source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace